NO20053530L - Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav - Google Patents

Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav

Info

Publication number
NO20053530L
NO20053530L NO20053530A NO20053530A NO20053530L NO 20053530 L NO20053530 L NO 20053530L NO 20053530 A NO20053530 A NO 20053530A NO 20053530 A NO20053530 A NO 20053530A NO 20053530 L NO20053530 L NO 20053530L
Authority
NO
Norway
Prior art keywords
multivalent
beta receptor
lymphotoxin
receptor antagonists
cancer
Prior art date
Application number
NO20053530A
Other languages
English (en)
Norwegian (no)
Other versions
NO20053530D0 (no
Inventor
Jeffrey L Browning
Ellen A Garber
Veronique Bailly
Original Assignee
Biogen Idec Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc filed Critical Biogen Idec Inc
Publication of NO20053530D0 publication Critical patent/NO20053530D0/no
Publication of NO20053530L publication Critical patent/NO20053530L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20053530A 2002-12-20 2005-07-19 Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav NO20053530L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US43515402P 2002-12-20 2002-12-20
PCT/US2003/041393 WO2004058191A2 (en) 2002-12-20 2003-12-22 Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
NO20053530D0 NO20053530D0 (no) 2005-07-19
NO20053530L true NO20053530L (no) 2005-09-20

Family

ID=32682169

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20053530A NO20053530L (no) 2002-12-20 2005-07-19 Multivalente lymfotoksin-beta-reseptorantagonister samt anvendelse derav

Country Status (8)

Country Link
US (1) US20060104971A1 (de)
EP (1) EP1583503A4 (de)
JP (1) JP2006515750A (de)
CN (1) CN100473664C (de)
AU (1) AU2003299984A1 (de)
CA (1) CA2511013A1 (de)
NO (1) NO20053530L (de)
WO (1) WO2004058191A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
EP1539793A4 (de) * 2002-07-01 2006-02-01 HUMANISIERTE ANTI-LYMPHOTOIN-BETA-REZEPTOR-ANTIKöRPER
AU2003256299A1 (en) * 2002-07-01 2004-01-19 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima
US7700097B2 (en) * 2003-06-27 2010-04-20 Biogen Idec Ma Inc. Purification and preferential synthesis of binding molecules
BRPI0509201A (pt) * 2004-03-23 2007-08-28 Biogen Idec Inc agentes de acoplamento de receptor e usos terapêuticos destes
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
EP2295080A3 (de) 2005-07-25 2011-06-22 Emergent Product Development Seattle, LLC B-Zell-Verringerung mit CD37-spezifischen und CD20-spezifischen Bindungsmolekülen
CN103073639A (zh) * 2006-03-17 2013-05-01 比奥根艾迪克Ma公司 稳定的多肽组合物
AU2016231617B2 (en) * 2006-06-12 2018-08-23 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
AU2014200661B2 (en) * 2006-06-12 2016-06-30 Aptevo Research And Development Llc Single-chain multivalent binding proteins with effector function
CN105837690A (zh) * 2006-06-12 2016-08-10 新兴产品开发西雅图有限公司 具有效应功能的单链多价结合蛋白
SG178002A1 (en) * 2006-10-20 2012-02-28 Biogen Idec Inc Treatment of demyelinating disorders
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
CN101990439A (zh) * 2007-07-06 2011-03-23 特鲁比昂药品公司 具有置于c末端的特异性结合结构域的结合肽
US20090155275A1 (en) * 2007-07-31 2009-06-18 Medimmune, Llc Multispecific epitope binding proteins and uses thereof
KR100967623B1 (ko) * 2008-02-22 2010-07-05 전남대학교산학협력단 림포톡신을 포함하는 자궁경부암 예방 또는 치료용 조성물
PT2132228E (pt) 2008-04-11 2011-10-11 Emergent Product Dev Seattle Imunoterapia de cd37 e sua combinação com um quimioterápico bifuncional
EP2844290A4 (de) * 2012-05-01 2015-12-16 Glaxosmithkline Llc Neuartige antikörper
AU2014210908B2 (en) * 2013-02-04 2019-02-14 University Of Huddersfield Composition comprising a TNFR agonist and at least one thioredoxin inhibitor for use in the treatment of carcinoma
TWI700295B (zh) 2013-12-16 2020-08-01 馬來西亞商Ｍａｂ探索私人有限公司 對會感染人類之腸病毒具有專一性之抗體
MA41044A (fr) 2014-10-08 2017-08-15 Novartis Ag Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
CA2973720A1 (en) * 2015-01-14 2016-07-21 Compass Therapeutics Llc Multispecific immunomodulatory antigen-binding constructs
KR102784293B1 (ko) 2015-09-21 2025-03-20 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
EP3359168A4 (de) * 2015-10-06 2019-08-07 Regents of the University of Minnesota Therapeutische verbindungen und verfahren
AU2019361096A1 (en) 2018-10-19 2021-06-03 Regents Of The University Of Minnesota NK engager molecules and methods of use thereof
AU2020401755A1 (en) * 2019-12-11 2022-08-04 Cilag Gmbh International Multispecific binding molecules comprising LTBR and EDB binding domains and uses thereof
EP4255929A2 (de) * 2020-12-02 2023-10-11 Vib Vzw Ltbr-agonist in kombinationstherapie gegen krebs
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US669941A (en) * 1898-12-17 1901-03-12 Electric Axle Light & Power Company Electric switch.
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
AU692146B2 (en) * 1990-06-27 1998-06-04 Biogen Idec Ma Inc. Lymphotoxin-beta, lymphotoxin-beta complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
WO1996022788A1 (en) * 1995-01-26 1996-08-01 Biogen, Inc. LYMPHOTOXIN-α/β COMPLEXES AND ANTI-LYMPHOTOXIN-BETA RECEPTOR ANTIBODIES AS ANTI-TUMOR AGENTS
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
TR200504220T2 (tr) * 1998-12-17 2007-04-24 Biogen Idec Ma Inc. Aktif limfotoksin-beta reseptör imunoglobülin şimeAktif limfotoksin-beta reseptör imunoglobülin şimerik proteinlerinin yüksek düzey ifadesi ve saflaştrik proteinlerinin yüksek düzey ifadesi ve saflaştırılması için bir yöntem.ırılması için bir yöntem.
AU2001247616B2 (en) * 2000-04-11 2007-06-14 Genentech, Inc. Multivalent antibodies and uses therefor
AU2001279678B2 (en) * 2000-06-30 2005-08-18 Innogenetics N.V. Differential diagnosis of neurological diseases
JP2004520810A (ja) * 2000-08-24 2004-07-15 ジェネンテック・インコーポレーテッド 腫瘍の診断と治療のための組成物と方法
TR200300478T2 (tr) * 2000-10-13 2004-10-21 Biogen Inc. Hümanize antiLT-ß-R antikorları
US20030133939A1 (en) * 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7576185B2 (en) * 2002-03-05 2009-08-18 Genentech, Inc. PRO34128 antibodies
EP1539793A4 (de) * 2002-07-01 2006-02-01 HUMANISIERTE ANTI-LYMPHOTOIN-BETA-REZEPTOR-ANTIKöRPER
RS20050481A (sr) * 2002-12-20 2007-08-03 Biogen Idec Ma Inc., Agensi limfotoksin beta receptora u kombinaciji sa hemoterapeutskim agensima

Also Published As

Publication number Publication date
JP2006515750A (ja) 2006-06-08
US20060104971A1 (en) 2006-05-18
EP1583503A2 (de) 2005-10-12
EP1583503A4 (de) 2006-08-09
WO2004058191A2 (en) 2004-07-15
CN1798765A (zh) 2006-07-05
AU2003299984A1 (en) 2004-07-22
NO20053530D0 (no) 2005-07-19
WO2004058191A3 (en) 2005-12-29
CN100473664C (zh) 2009-04-01
CA2511013A1 (en) 2004-07-15

Similar Documents

Publication Publication Date Title
BRPI0617165A2 (pt) Compostos inibidores mek, composições farmacêuticas que os contem e métodos de uso dos mesmos
ATE419849T1 (de) Diaminotriazole derivate und deren verwendung als protein kinase inhibitoren
WO2004058191A3 (en) Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
NO20070514L (no) Pyrrolotriazin kinase inhibitorer
NO20170633A1 (no) Forbindelser av indolamin-2,3-dioksygenase for anvendelse i behandling av kreft i kombinasjon med et anti-PD-1 antistoff .
BRPI0408247A (pt) usos de antagonistas e agonistas de il-23 e reagentes relacionados
NO20070585L (no) Humane anti-KIR antistoff.
CY1106933T1 (el) Ενωσεις πυριμιδινης
EA201301072A1 (ru) Антитела против il-23p19 и их применение
DK1802625T3 (da) Disubstituerede pyrazolobenzodiazepiner der er nyttige som inhibitorer af CDK2 og angiogenese og til behandling af bryst-, tyktarms-, lunge- og prostatacancer
NO20064976L (no) Azanidoler som er nyttige som inhibitorer av rock og andre proteinkinaser
NO20052595D0 (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
BR112012010027A2 (pt) dispositivo para uso pessoal em uma fototerapia
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
DE602004012083D1 (de) Substituirte benzosulfonamide als potenzierungsmittel von glutamatrezeptoren
EA200500721A1 (ru) Пиримидины, ингибирующие chk, pdk и акт, их получение и применение в качестве лекарственных средств
CY1113247T1 (el) Νουκλεϊνικα οξεα με τιτλο 273ρ4β7 και η χρηση τους στην ανιχνευση καρκινου
EA200401284A1 (ru) Замещённые бензазолы и их применение в качестве ингибиторов киназы raf
NO20074366L (no) Fremgangsmate for a behandle gefitmibresistent kreft
AR064458A1 (es) Antagonistas especificos de vegf para terapia adyuvante y neoadyuvante y el tratamiento de tumores en estadios tempranos
EA201070425A1 (ru) Покрытие скважины с необсаженным стволом
ECSP077222A (es) Anticuerpos monoclonales humanos contra interleucina-4 humana (il-4)
DE60307856D1 (de) Antitumorverbindung und ihre therapeutischen verwendungen
PT1325011E (pt) Metodos e compostos para tratamento de doencas proliferativas
ATE411981T1 (de) Tetrahydrocarbazolderivate und deren pharmazeutische verwendung

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application